A new clinical trial suggests that semaglutide — the active ingredient in the widely used drugs Ozempic and Wegovy — may help ...

(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online in JAMA Psychiatry. Christian S.

For years, people taking GLP-1 type drugs (e.g., Ozempic, Wegovy) have noticed that the medicines didn’t just help them to ...

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

Studies show promising results for semaglutide as a potential treatment for alcohol use disorder. Semaglutide, a GLP-1 drug, was initially used for type 2 diabetes treatment and weight loss. While ...

A study of 48 people with signs of moderate alcohol-use disorder found that those taking low doses of semaglutide – the generic name of Ozempic – for nine weeks saw significantly greater ...

“These data suggest the potential of semaglutide and similar drugs to fill an unmet need for the treatment of alcohol use disorder,” said senior author Klara Klein of the University of North ...

A study published in JAMA Psychiatry enrolled 48 adults between ages 21 and 65 who had been diagnosed with alcohol use disorder but were not actively seeking treatment. Half received semaglutide ...

2/20/25 (LAPost.com) — New research suggests semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, could help people reduce their alcohol consumption. The study, published in ...